http://www.fpnotebook.com/
Bicarbonate SupplementationAka: Polycitra, Shohl Solution, Oral Sodium Bicarbonate
- See Also
- Intravenous Sodium Bicarbonate for Resuscitation
- Indications
- Oral Preparations for Renal Tubular Acidosis
- Potassium Citrate (Polycitra)
- Concentration: 500 mg per 5 ml
- Base Concentration: 2 meq per 1 ml
- Oral Sodium Bicarbonate (325 mg and 650 mg tablets)
- Base Concentration: 4 meq per 325 mg tablet
- Citric Acid (Shohl Solution)
- Concentration: 140 grams per 1000 ml
- Base concentration: 1 meq per 1 ml
- Potassium Citrate (Polycitra)
- Oral Dosing in Renal Tubular Acidosis
- Distal RTA (low dose): 1-2 meq/kg/day
- Proximal RTA (high dose): 10-15 meq/kg/day
Sodium citrate and citric acid (C0304465) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| English | CITRIC ACID/SODIUM CITRATE, Shohl's solution, Sodium citrate and citric acid |
| Spanish | citrato de sodio y acido citrico, solucion de Shohl |
| Parent Concepts | Citric Acid (C0055819), sodium citrate (C0142825), Drug allergen (C1320237) |
| Sources | SCTSPA, SNOMEDCT, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Polycitra (C0722698) | |
|---|---|
| Definition (NCI) | A combination of sodium citrate and potassium citrate with alkalizing and antiurolithic effects. Polycitra is metabolized to bicarbonates, thereby increasing urinary pH by increasing the excretion of free bicarbonate ions. A rise in urinary pH increases the solubility of cystine in the urine and the ionization of uric acid to more soluble urate ion. In addition, increased urinary citrate and pH decreases calcium ion activity by increasing calcium complexation to dissociated anions and thus decreasing the saturation of calcium oxalate. By increasing the level of plasma bicarbonate this agent also buffers excess hydrogen ion concentration and raises blood pH, thereby reversing the clinical manifestations of acidosis. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| English | Polycitra |
| Parent Concepts | Alkalinizing Agent Preparation (C1510848) |
| Sources | NCI, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
